Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 6Terminated 3Active not recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × Clarithromycin × Clear all
NCT04843579 2023-10-25

ClaSPd

Weill Medical College of Cornell University

Phase 2 Terminated
4 enrolled 9 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02516696 2023-06-05

BiRd vs Rd

Weill Medical College of Cornell University

Phase 3 Terminated
12 enrolled 19 charts
Plasma cell

Multiple Myeloma

NCT01374217 2018-12-10

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
14 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡